PTEN and VEGF: Possible predictors for sentinel lymph node micro-metastasis in breast cancer

Biomedicine and Pharmacotherapy

Volumn 61, Issue 9 SPEC. ISS., 2007, Pages 558-561

  Zhu, Li ^a   T Y Loo, Wings ^b   Louis, W C Chow ^b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIMED Medical Institute   (Hong Kong)

Author keywords

Breast neoplasm; Micro metastasis; PTEN; VEGF

Indexed keywords

EOSIN; HEMATOXYLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; VASCULOTROPIN;

ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; BONE MARROW EXAMINATION; BREAST CANCER; CANCER PATIENT; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; STAINING;

EID: 35348832517     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.08.015     Document Type: Article

References (23)

1. Li D.M., and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57 (1997) 2124-2129
2. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15 (1997) 356-362
3. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 (1997) 64-67
4. Freihoff D., Kempe A., Beste B., Wappenschmidt B., Kreyer E., Hayashi Y., et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer 79 (1999) 754-758
5. Feilotter H.E., Coulon V., McVeigh J.L., Boag A.H., Dorion-Bonnet F., Duboue B., et al. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79 (1999) 718-723
6. Jiang Y.A., Fan L.F., Jiang C.Q., Zhang Y.Y., Luo H.S., Tang Z.J., et al. Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J Gastroenterol 9 (2003) 491-494
7. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246 (1989) 1309-1312
8. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., and Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1308
9. Bosari S., Lee A.K., DeLellis R.A., Wiley B.D., Heatley G.J., and Silverman M.L. Microvessel quantitation and prognosis in invasive ductal carcinoma. Hum Pathol 23 (1992) 755-761
10. Pantel K., Cote R.J., and Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91 (1999) 1113-1124
11. Hellman S. Stopping metastases at their source. N Engl J Med 337 (1997) 996-997
12. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 278 (1997) 1054-1059
13. Solakoglu O., Maierhofer C., Lahr G., Breit E., Scheunemann P., Heumos I., et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A 99 (2002) 2246-2251
14. Klein C.A., Blankenstein T.J., Schmidt-Kittler O., Petronio M., Polzer B., Stoecklein N.H., et al. Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer. Lancet 360 (2002) 683-689
15. Schmidt-Kittler O., Ragg T., Daskalakis A., Granzow M., Ahr A., Blankenstein T.J., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100 (2003) 7737-7742
16. Hu X.C., Wang Y., Shi D.R., Loo W.T.Y., and Chow L.W.C. Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells. Oncology 64 (2003) 160-165
17. Zhu L., Loo W.T., and Chow L.W. Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. Biomed Pharmacother 59 Suppl. 2 (2005) s355-s358
18. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dahia P.L., et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155 (1999) 1253-1260
19. Depowski P.L., Rosenthal S.I., and Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14 (2001) 672-676
20. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273 (1998) 13375-13378
21. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10 (1998) 262-267
22. Giri D., and Ittmann M. Inactivation of the PTEN tumor suppressorgene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 30 (1999) 419-424
23. Bose S., Crane A., Hibshoosh H., Mansukhani M., Sandweis L., and Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol 33 (2002) 405-409